2022 Rome Action Plan on Paediatric HIV & TB
IMPAACT commits to:
222. Determine dosing and safety of DTG dispersible tablets in newborns by third quarter 2024
223. Determine safety, dosing, and acceptability of long-acting injectable ART with cabotegravir and rilpivirine in adolescents by second quarter of 2024 and children over age 2 years by second quarter of 2024.
224. IMPAACT to collaborate with GAP-f partners and appropriate research networks to implement a platform trial to assess innovative options to deliver postnatal prophylaxis